Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

COLOSTEO

Financiado

Cerrado

Nutraceutical supplementation based on colostrum for prevention of osteoporosis

Osteoporosis constitutes a major public health concern. The economic burden of osteoporotic fractures in EU is expected to increase 25% by 2025 compared to 2010. These estimates may indicate an inefficiency of current drugs for os... ver más

31/12/2021

UNIVERSITY OF THES...

828K€

Presupuesto del proyecto: 828K€

Líder del proyecto

PANEPISTIMIO THESSALIAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-12-31

MSCA-RISE-2017: Research and Innovation Staff Excha... Objective:The RISE scheme will promote international and inter-sector collaboration through research...

I+D

Cerrada hace 8 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

UNIVERSITY OF THESSALY - UTH

207.00K€ | Lider

Saluris network

207.00K€ | Participante

BIOMECHANICAL SOLUTIONS

207.00K€ | Participante

U.PORTO

207.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 49 meses Fecha Inicio: 2017-11-22
Fecha Fin: 2021-12-31

Líder del proyecto

PANEPISTIMIO THESSALIAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 828K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Osteoporosis constitutes a major public health concern. The economic burden of osteoporotic fractures in EU is expected to increase 25% by 2025 compared to 2010. These estimates may indicate an inefficiency of current drugs for osteoporosis. Actually, the use of pharmacological agents for osteoporosis has been decreasing in EU, probably due to the reported side effects. Therefore, there is a need for innovative agents to reduce the burden of osteoporosis. Colostrum is a promising agent against bone loss since it has natural constituents that are directly involved in bone metabolism. As a nutraceutical, colostrum confers an advantage over pharmacological drugs since it can avoid side effects. However, the possibility of its use as a nutraceutical agent for osteoporosis have only received attention within the scientific community. The knowledge produced on the effects of colostrum on bone metabolism has not yet been transferred to the market because academic institutions lack on expertise to create a new product. On the other hand, industry has knowledge on product development, but lack expertise on research skills. In accordance, what hinders the creation of an innovative product based on colostrum for prevention of osteoporosis is the absence of an intersectorial collaboration. As consequence, there is a clearly gap between research on the matter and its application. COLOSTEO aims to fill in this gap by creating an intersectorial collaboration to exchange knowledge and expertise towards the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis. This aim will be achieved by bridging two academic with two industrial institutions that through intersectorial secondments will exchange knowledge, ideas and expertise towards the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores